His primary areas of study are Immunology, T cell, Cytotoxic T cell, CD8 and IL-2 receptor. Immunotherapy, Adoptive cell transfer and Immune system are the core of his Immunology study. His Immunotherapy study incorporates themes from Improved survival and Histology.
As part of his studies on T cell, Christopher A. Klebanoff often connects relevant subjects like Cancer research. Particularly relevant to Interleukin 21 is his body of work in Cytotoxic T cell. His studies deal with areas such as Interleukin 2 and Cell biology as well as CD8.
His primary areas of investigation include Immunology, CD8, T cell, Cancer research and Immunotherapy. In his work, Cellular differentiation is strongly intertwined with Cytotoxic T cell, which is a subfield of Immunology. His CD8 research also works with subjects such as
His work investigates the relationship between T cell and topics such as FOXP3 that intersect with problems in Acquired immune system. His Cancer research research is multidisciplinary, relying on both Cell, Cytokine, Tumor microenvironment, Apoptosis and T-cell receptor. His biological study deals with issues like Oncology, which deal with fields such as Multiple cancer, Histology and Immune checkpoint inhibitors.
His main research concerns T-cell receptor, Cancer research, Cancer immunotherapy, Antigen and Receptor. His T-cell receptor research integrates issues from Epitope, Cancer, In vitro and Computational biology. His research in Cancer research intersects with topics in Tumor microenvironment, Phase i study, Chimeric antigen receptor and Head and neck.
His research investigates the connection with Tumor microenvironment and areas like Genetic enhancement which intersect with concerns in Immunotherapy. The concepts of his Cancer immunotherapy study are interwoven with issues in T cell and Adoptive cell transfer. His research integrates issues of Cytotoxic T cell and Effector in his study of T cell.
Christopher A. Klebanoff mainly focuses on T cell, Cancer research, Cancer immunotherapy, T-cell receptor and Effector. Christopher A. Klebanoff combines subjects such as Cytotoxic T cell and Antigen with his study of T cell. His work carried out in the field of T-cell receptor brings together such families of science as Apoptosis, Adoptive cell transfer, Chimeric antigen receptor and Fas ligand.
Christopher A. Klebanoff interconnects Autophagy, Tumor microenvironment, CD8, Immune tolerance and Histone in the investigation of issues within Effector.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann.
Nature Genetics (2019)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
Luca Gattinoni;Steven E. Finkelstein;Christopher A. Klebanoff;Christopher A. Klebanoff;Paul A. Antony.
Journal of Experimental Medicine (2005)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
Luca Gattinoni;Christopher A. Klebanoff;Christopher A. Klebanoff;Douglas C. Palmer;Claudia Wrzesinski.
Journal of Clinical Investigation (2005)
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
Willem W. Overwijk;Marc R. Theoret;Steven E. Finkelstein;Deborah R. Surman.
Journal of Experimental Medicine (2003)
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
Christopher A. Klebanoff;Luca Gattinoni;Parizad Torabi-Parizi;Keith Kerstann.
Proceedings of the National Academy of Sciences of the United States of America (2005)
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4 T helper cells and hindered by naturally occurring T regulatory cells.
Paul A. Antony;Ciriaco A. Piccirillo;Akgül Akpinarli;Steven E. Finkelstein.
Journal of Immunology (2005)
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Madhusudhanan Sukumar;Jie Liu;Yun Ji;Murugan Subramanian.
Journal of Clinical Investigation (2013)
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
Christopher A. Klebanoff;Steven E. Finkelstein;Deborah R. Surman;Michael K. Lichtman;Michael K. Lichtman.
Proceedings of the National Academy of Sciences of the United States of America (2004)
CD8+ T‐cell memory in tumor immunology and immunotherapy
Christopher A. Klebanoff;Luca Gattinoni;Nicholas P. Restifo.
Immunological Reviews (2006)
Paths to stemness: building the ultimate antitumour T cell
Luca Gattinoni;Christopher A. Klebanoff;Nicholas P. Restifo.
Nature Reviews Cancer (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: